Asset Publisher

angle-left Stéphane Laporte, PhD

Senior Scientist, RI-MUHC, Glen site

Metabolic Disorders and Complications Program

Professor, Department of Medicine, Division of Endocrinology and Metabolism, Faculty of Medicine, McGill University



G protein-coupled receptor • molecular pharmacology • cell imaging • cardiovascular diseases • pre-term birth.

Research Focus

My research focuses on understanding the molecular and cellular mechanisms regulating G protein-coupled receptors (GPCRs). We are interested in ligand-directed signaling, and the development of novel molecules with allosteric, biased signaling modes of action, in particular for the prostanglandin PG2α (FP) and Angiotensin type I (AT1) receptors. Using innovative imaging and biophysical approaches we also study the dynamics of protein complexes involved in receptor trafficking and signaling for different GPCRs, in particular for the angiotensin II type 1 and Bradykinin B2 receptors. Our laboratory is involved in developing novel fluorescently tagged biosensors for studying, in live cells, GPCR signaling and trafficking, with the goal of identifying small molecules regulator of these responses. Our research program aims at providing new insights into the molecular details of GPCR signaling and trafficking to improve hormone and drug efficacy, especially in cardiovascular diseases, inflammation, pre-term birth and cancer.

Selected Publications

Click on Pubmed to see my current publications list

  • Goupil E, Wisehart V, Khoury E, Zimmerman B, Jaffal S, Hébert TE, Laporte SA. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol Endocrinol. 2012 Jul;26(7):1189-202. doi: 10.1210/me.2011-1245. Epub 2012 May 25. PMID: 22638073

  • Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A, Bouvier M, Laporte SA. Differential &beta-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal. 2012 Apr 24;5(221):ra33. doi: 10.1126/scisignal.2002522. PMID: 22534132

  • Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hébert TE, Laporte SA. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. J Biol Chem. 2010 Aug 13;285(33):25624-36. doi: 10.1074/jbc.M110.115196. Epub 2010 Jun 15. PMID: 20551320